Madrigal Pharmaceuticals (MDGL) Capital Expenditures Growth (3y) (2013 - 2026)
Madrigal Pharmaceuticals (MDGL) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 16.34 Bn | 16.11 Bn | - | 379.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 379.10% |
| Dec 31, 2025 | -122.40% |
| Sep 30, 2025 | 180.46% |
| Dec 31, 2024 | 134.76% |
| Sep 30, 2024 | -127.41% |
| Jun 30, 2024 | 303.10% |
| Mar 31, 2024 | 100.94% |
| Dec 31, 2023 | 369.66% |
| Sep 30, 2023 | 383.46% |
| Jun 30, 2023 | 114.41% |
| Mar 31, 2023 | -51.87% |
| Dec 31, 2022 | -67.68% |
| Sep 30, 2022 | 164.48% |
| Jun 30, 2022 | 371.77% |
| Mar 31, 2022 | 8.24% |
| Dec 31, 2021 | 141.73% |
| Sep 30, 2021 | 56.68% |
| Mar 31, 2021 | 253.03% |
| Dec 31, 2020 | -56.91% |
| Jun 30, 2020 | -61.54% |